The insider sales are mechanically linked to option exercises and are immaterial relative to JNJ's market cap. No bearish signal. Monitor for any future open-market purchases by C-suite as a more meaningful signal of conviction. The next quarterly earnings (expected late October) will be the primary catalyst for JNJ shares.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 19 $273.41entry
- T+1 · 3mo ago −2.21%α −1.37% · $267.37
- T+5 · 3mo ago −1.25%α −0.86% · $270.00
- T+20 · 2mo ago −1.17%α +0.79% · $270.22
- T+60 · 5d ago +3.70%α +5.25% · $283.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Joaquin Duato and EVP Jennifer Taubert sold a combined $30.65M in open-market stock over a 5-day window, with Duato's $32.2M sale being the dominant event. The sales are tied to derivative exercises (Duato exercised 123,291 options at $115.67/share, Taubert exercised 15,000 options at $115.67/share), which is a routine pattern for tax and diversification purposes. At $632.3B market cap, the total open-market sales represent ~0.005% of market cap, a trivial amount that does not signal a bearish view on the company's prospects. The cluster is neutral, as the dollar value is immaterial relative to company size and the sales are mechanically linked to option exercises.
Key Financial Metrics
Key Facts
- CEO Joaquin Duato sold 123,291 shares in open-market transactions for ~$32.2M on 2026-08-13, concurrent with exercising 123,291 options at $115.67/share
- EVP Jennifer Taubert sold 15,000 shares for ~$3.95M on 2026-08-17, concurrent with exercising 15,000 options at $115.67/share
- Total open-market sales: $30.65M, representing ~0.005% of JNJ's $632.3B market cap
- Both sales are directly tied to derivative exercises, a routine pattern for tax withholding and portfolio diversification, not a bearish signal
- No open-market purchases in the cluster; all activity is sell-side and option-exercise-driven
Financial Impact
Total open-market sales of $30.65M represent ~0.005% of JNJ's $632.3B market cap, economically trivial
Risk Factors
- Insider sales could be misinterpreted as bearish by algorithmic trading systems
- CEO selling near all-time-high stock price (~$271) may create negative sentiment among retail investors
- No insider buying to offset the selling pattern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-JNJ-1787092304730 |
Track record
21 reports on JNJ
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Viewing Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers